The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Correction to Celcuity Gets FDA Approval Headline
Celcuity wins approval for breast cancer drug Revtorpyk
Celcuity gains FDA approval for closely watched breast cancer drug
Celcuity's breast cancer drug approved, its first
Celcuity got its cancer drug approved. Then its stock dipped
Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast…
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a…
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.
